Rubicon Research valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026
Price multiples — at each FY-end close
89.32×—
19.97×—
13.30×—
Enterprise multiples
13.34×—
57.34×—
64.64×—
Yield
1.1%—
−0.1%—
Reference — adjusted share basis
₹1,559.30—
₹17.46₹14.95
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

RUBICON₹1,559.30

Rubicon Research Ltd.

· Pharma & Health
₹ CrorePeersSHILPAMEDSPARCSTARSUPRIYAPARKHOSPSTHYROCAREMETROPOLISMARKSANSMcap ₹25,742 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E—89.32
P/B—19.97
P/Sales—13.30
Enterprise Multiples
EV/Sales—13.34
EV/EBITDA—57.34
EV/EBIT—64.64
Yield
Earnings Yield %—1.12
FCF Yield %—-0.09
Reference — adjusted share basis
Price (FY-end close, adj.)—1,559.30
EPS (adj.)14.9517.46
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.